OmniRx Research // Press Kit

Press Kit: PBM Reality 2026 Editorial Review Pending

Published 2026-05-09 · Embargo: none, available for immediate publication · Read the full study · Download data.json

Medical disclaimer for republishers OmniRx research is for informational purposes. Drug pricing data reflects publicly disclosed formulary information; individual experience varies. When republishing or quoting, please retain the editorial-review-pending notation and the link to the medical disclaimer in the full study.
Correction, 13 November 2026 This study originally included a 53-record drug-interaction component. Those records were compiled by hand and were not checked against current FDA label text, so the component and every figure derived from it (severity shares, the most-flagged-drugs ranking and the interaction-to-coverage overlap) have been withdrawn from this press kit, the study page and data.json. The patient-assistance and formulary findings are unchanged. Archived earlier versions of the study may still contain the withdrawn component.

Dataset summary

Three quotable findings

"The modal patient assistance program in our database caps eligibility at 400 percent of the Federal Poverty Level, the same line the Affordable Care Act used for premium subsidies. That clustering is not coincidence. It tells you patient assistance programs are designed against visible regulatory thresholds, not against the actual distribution of patient need."

Attribute to: Vincent, OmniRx Research

"Sixty-six percent of patient assistance programs are run by the drug manufacturer, not by an independent nonprofit. A manufacturer PAP is a marketing-spend line item that covers only that manufacturer's portfolio. The patient ends up navigating a patchwork of brand-specific programs that the FTC's PBM reports describe at the wholesale layer and that we now document at the consumer-facing layer."

Attribute to: Vincent, OmniRx Research

Target outlets

Investigative health desks we believe will find this most useful

KFF Health News (PBM and drug pricing beat); STAT News (Pharmalot, drug pricing investigations); ProPublica (health and prescription drug investigations); Bloomberg drug pricing desk; Healthcare Dive; Axios Vitals; the Drug Channels readership for industry context. Mark Cuban Cost Plus Drugs PR list welcome.

Headline numbers for editors

Downloads

Primary sources cited in the study

Media contact

Vincent, OmniRx Research

Email: vincent@deepsynthesis.org

Available for: written quotes (24 hour turnaround), data drill-down requests on any of the three datasets, on-record commentary on PBM structure, formulary tier opacity, patient assistance program design, and consumer-facing pharmacy navigation. We will route requests for clinical interpretation to a credentialed clinician once editorial review is finalized; for now, all clinical phrasing is conservative and editorial-review-pending.

Response time: typically same-day during ET business hours.

About OmniRx

OmniRx is an independent consumer pharmacy intelligence site at omnirx.org. We publish first-party drug interaction reference, formulary explainers, patient assistance program directories, and PBM industry research for U.S. patients. OmniRx is part of the DeepSynthesis Lattice, a constellation of niche research sites covering ecommerce, finance, education, and health verticals. We are not affiliated with any insurer, PBM, or pharmaceutical manufacturer.